Previous 10 | Next 10 |
Stock Market Today Mid-Morning Updates On Tuesday, the Dow Jones Industrial Average is up by 350 points after retreating for the last 3 sessions. All major indexes were green today despite continued fears of rising inflation. Also, rising interest rates continue to weigh in on i...
The decision by Pfizer (NYSE:PFE) to acquire the commercial-stage biopharma company, Biohaven Pharmaceutical (BHVN) for nearly $12 billion has revived the beaten-down biotech space on Tuesday. SPDR S&P Biotech ETF (XBI) is trading higher after three sessions of declines to record the...
Gainers: Biohaven Pharmaceutical (BHVN) +71%. AdaptHealth (AHCO) +31%. Evaxion Biotech (EVAX) +25%. Assertio (ASRT) +22%. Haemonetics (HAE) +16%. Losers: Bausch Health (BHC) -26%. GoodRx (GDRX) -24%. Akanda (AKAN) -21%. Novavax ...
MONSEY, N.Y., May 10, 2022 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating whether the directors of Biohaven Pharmaceutical Holding Company, Ltd. (ticker: BHVN) (“Biohaven”) acted in the best interests of Biohaven shareholders in approving the sale...
Biohaven Pharmaceuticals press release (NYSE:BHVN): Q1 Non-GAAP EPS of -$1.62 beats by $0.65. Revenue of $318.85M (+627.6% Y/Y) beats by $135.14M Pfizer and Biohaven Pharmaceutical Holding Company today announced that the companies have entered into a definitive agreement under which Pfi...
Biohaven Reports First Quarter 2022 Financial Results and Reports Recent Business Developments PR Newswire Pfizer Inc. and Biohaven Pharmaceutical Holding Company Ltd. today announced that the companies have entered into a definitive agreement under which Pfizer will a...
Pfizer to commercialize NURTEC ® ODT (rimegepant), an innovative compound for the prevention and acute treatment of migraine, a condition with high unmet need Expands Pfizer’s innovative Internal Medicine pipeline to drive enhanced growth through 2030 and beyon...
Biohaven to Discuss First Quarter 2022 Financial Results and Recent Business Developments on May 11, 2022 PR Newswire NEW HAVEN, Conn. , May 9, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage bi...
Biohaven Pharmaceuticals (NYSE:BHVN) is scheduled to announce Q1 earnings results on Monday, May 9th, before market open. The consensus EPS Estimate is -$2.27 (+23.6% Y/Y) and the consensus Revenue Estimate is $183.71M (+319.4% Y/Y). Over the last 2 years, BHVN has beaten EPS estimates 50% of...
Gainers: Finch Therapeutics (FNCH) +46%. Zymeworks (ZYME) +44%. Lantheus (LNTH) +13%. BeiGene (BGNE) +12%. Inari Medical (NARI) +11%. Losers: Accolade (ACCD) -55%. Aldeyra Therapeutics (ALDX) -15%. Venus Concept (VERO) -14%. Bio...
News, Short Squeeze, Breakout and More Instantly...
Biohaven Pharmaceutical Holding Company Ltd. Company Name:
BHVN Stock Symbol:
NYSE Market:
Biohaven Pharmaceutical Holding Company Ltd. Website:
2024-05-29 12:00:07 ET Brian Skorney from Robert W. Baird issued a price target of $58.00 for BHVN on 2024-05-29 09:57:00. The adjusted price target was set to $58.00. At the time of the announcement, BHVN was trading at $30.31. The overall price target consensus is at $...
2024-05-29 11:00:21 ET Leonid Timashev from RBC Capital issued a price target of $59.00 for BHVN on 2024-05-29 09:14:00. The adjusted price target was set to $59.00. At the time of the announcement, BHVN was trading at $28.69. The overall price target consensus is at $23...